Torrent Pharmaceuticals Shares in Focus; Announces Record Date for Interim Dividend

Torrent Pharmaceuticals has fixed February 1, 2025, as the record date for identifying eligible shareholders for an interim dividend, subject to approval at the board meeting on January 24, 2025.

Corporate Action History 

The company has declared several key dividends over the past two years. On January 12, 2024, an interim dividend of ₹22 was declared, with the record date set for February 12, 2024.

In 2023, an interim dividend of ₹14 was paid, with the record date on February 3, 2023. Additionally, the company declared final dividends in previous years: ₹8 per share on June 23, 2023, with a record date of May 30, 2023, and ₹6 per share on June 21, 2024, with a record date of May 24, 2024.

Q2 FY25 Financial Highlights

Torrent Pharmaceuticals reported a 17% year-on-year increase in consolidated net profit for the September quarter (Q2 FY25), reaching ₹453 crore, up from ₹386 crore in the same period last year.

The company’s revenue from operations grew by 9% year-on-year, totalling ₹2,889 crore in Q2 FY25, compared to ₹2,660 crore in Q2 FY24.

The company attributed some of the shortfall to a scheduled maintenance shutdown in August at its insulin manufacturing facility.

Torrent Pharma’s India business saw a 13% year-on-year growth, driven by strong performance in its focus therapies and a 14% growth in its chronic business. Operationally, the company reported an EBITDA of ₹939 crore, reflecting a margin of 32.5%.

Share Price Performance

Torrent Pharmaceuticals’ share price traded 0.11% higher at ₹3,238.85 on the NSE at 9:30 AM. The stock opened at ₹3,239.70, up from the previous close of ₹3,235.35.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.